| 149.01 0.89 (0.6%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 174.83  |
1-year : | 204.21 |
| Resists | First : | 149.69 |
Second : | 174.83 |
| Pivot price | 139.32 |
|||
| Supports | First : | 136.29 |
Second : | 128 |
| MAs | MA(5) : | 144.72 |
MA(20) : | 137.43 |
| MA(100) : | 147.74 |
MA(250) : | 207.55  |
|
| MACD | MACD : | 1.6 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 89.9 |
D(3) : | 86.7 |
| RSI | RSI(14): 65.9 |
|||
| 52-week | High : | 354.88 | Low : | 126.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PODD ] has closed Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 149.87 - 150.43 | 150.43 - 150.88 |
| Low: | 143.51 - 144.21 | 144.21 - 144.76 |
| Close: | 147.95 - 149.04 | 149.04 - 149.91 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Fri, 23 Oct 2026
Insulet Corporation Estimates – NASDAQ:PODD - TradingView
Thu, 22 Oct 2026
Insulet (NASDAQ:PODD): A Growth-at-a-Reasonable-Price Case With Strong Expansion - ChartMill
Thu, 22 Oct 2026
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Tue, 20 Oct 2026
Bronstein, Gewirtz & Grossman (PODD) Investigation: Bronstein, Ge - The National Law Review
Sat, 17 Oct 2026
MONDAY INVESTOR DEADLINE: Insulet Corporation (PODD) Investors wi - The National Law Review
Thu, 17 Sep 2026
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 69 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 106.8 (%) |
| Shares Short | 5,360 (K) |
| Shares Short P.Month | 4,450 (K) |
| EPS | 5.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.51 |
| Profit Margin | 12.2 % |
| Operating Margin | 16.1 % |
| Return on Assets (ttm) | 9.7 % |
| Return on Equity (ttm) | 26 % |
| Qtrly Rev. Growth | 23.5 % |
| Gross Profit (p.s.) | 31.29 |
| Sales Per Share | 43.97 |
| EBITDA (p.s.) | 8.86 |
| Qtrly Earnings Growth | 328.6 % |
| Operating Cash Flow | 511 (M) |
| Levered Free Cash Flow | 237 (M) |
| PE Ratio | 27.9 |
| PEG Ratio | 1 |
| Price to Book value | 7.26 |
| Price to Sales | 3.38 |
| Price to Cash Flow | 20.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|